ARTICLE | Company News
Merck KGaA, Ono Pharmaceutical deal
October 10, 2011 7:00 AM UTC
Ono granted Merck's Merck Serono S.A. division exclusive rights outside of Japan, Korea and Taiwan to develop and commercialize multiple sclerosis (MS) compound ONO-4641. The sphingosine 1-phosphate (S1P) receptor agonist is in Phase II testing to treat relapsing-remitting MS (RRMS). Ono will receive ¥1.5 billion ($19.5 million) up front and is eligible for milestones. ...